Surface Oncology to Participate in Upcoming March Investor Conferences
February 24 2021 - 7:00AM
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology
company developing next-generation therapies targeting the tumor
microenvironment, today announced that Rob Ross, M.D., incoming
chief executive officer, will participate in the following virtual
investor conferences:
- Cowen 41st Annual Healthcare
Conference, Monday, March 1, 2021, at 10:20 a.m. ET as part of the
Novel IO panel.
- H.C. Wainwright Global Life
Sciences Conference, March 9-10, 2021, presentation recording will
be available to investors during the course of the conference.
The presentations will focus on Surface’s lead programs, SRF617
(targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s
emerging pre-clinical program, SRF114 (targeting CCR8).
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment. Its pipeline includes two wholly-owned
clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388),
as well as a preclinical program focused on depleting regulatory T
cells via targeting CCR8 (SRF114). In addition, Surface has two
partnerships with major pharmaceutical companies: a collaboration
with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration
with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).
Surface’s novel cancer immunotherapies are designed to achieve a
clinically meaningful and sustained anti-tumor response and may be
used alone or in combination with other therapies. For more
information, please visit www.surfaceoncology.com.
Contacts:
InvestorsMatt Lanematt@gilmartinir.com617-901-7698
MediaMatthew
Corcoranmcorcoran@tenbridgecommunications.com617-866-7350
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Apr 2023 to Apr 2024